A large body of evidence aimed to evaluate the bFGF role in CRC; this is proven by the considerable amount of assessment of the potential treatments and the discoveries of its biological cross-talk, e.g., with K-RAS signaling [95,96]. Here, FGF2 is linked to colorectal carcinoma.